EUCTR2021-004601-47-HUActive, not recruitingPhase 1
A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE) - VICTORION-PLAQUE
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- ovartis Pharma AG
- Enrollment
- 600
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Written informed consent must be obtained before any assessment is performed.
- •2. Male or female =18 years or =80 years of age at signing of informed consent.
- •3. Fasting LDL-C local lab value at the Screening Visit of either i) =100 mg/dL if on statin therapy but not on a maximally tolerated statin therapy; ii) =150 mg/dL if statin naive and without documented statin intolerance; or iii) =70 mg/dL if on a stable (=4 weeks) dose of maximally tolerated statin therapy or if statin intolerant.
- •4. Participants may be pre-identified based on a CCTA or an invasive angiography that is performed as part of standard of care within 12 months prior to the participant's Screening Visit demonstrating:
- •Presence of coronary artery plaque with visual diameter stenosis <50% or
- •Coronary artery plaque with visual artery stenosis >50% but Fractional Flow Reserve (FFR) >0.8 by special wire measurement (CCTA or coronary angiography)
- •5. Fasting LDL-C local lab value =70 mg/dL at the assessment performed during the Statin Optimization Period 3 Visit for participants going through the Statin Optimization Period.
- •6. Participants having NOCA* confirmed by CCTA with FFRCT >0.8 and CT-adapted Leaman score >5** or coronary artery plaque with visual diameter stenosis >50% but with FFRCT >0.8 and CT-adapted Leaman score >5 without previous cardiovascular events.
- •*=NOCA is defined as the presence of coronary artery plaque with visual diameter stenosis <50%.
- •**=CT-adapted Leaman score, which includes information on lesion localization, plaque composition, degree of stenosis by CCTA is demonstrated to be an independent long-term predictor of hard cardiac events.
- •A standard of care CCTA may serve as the study baseline CCTA scan if it is performed within 3 months prior to the participant's Screening Visit and meets the inclusion criteria of FFRCT >0.8 and CT-adapted Leaman score >5, which will be assessed by the Imaging Core Lab.
- •7. At the Baseline Visit, participants must be on a stable (=4 weeks) dose of maximally tolerated statin therapy. Participants not on maximally tolerated statin therapy and who do not have documented statin intolerance can be screened but must enter the study via a Statin Optimization Period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 330
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 270
Exclusion Criteria
- •1. Previous myocardial infarction (MI), or prior coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)].
- •2. Planned revascularization (PCI or CABG).
- •3. Previous ischemic cerebrovascular event including:
- •Prior ischemic stroke thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus.
- •History of prior percutaneous or surgical carotid artery revascularization.
- •4. History of Peripheral Artery Disease (PAD):
- •Prior documentation of a resting ankle-brachial index <0.85.
- •History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery.
- •Prior non-traumatic amputation of a lower extremity due to peripheral artery disease.
- •5. Cardiac disorders, including any of the following:
- •Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, atrial fibrillation) within 3 months prior to randomization that is not controlled by medication or via ablation at the time of the Screening Visit.
- •Complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) prior to randomization.
- •6. NOCA participant who was prescreened by the Investigator with visual diameter stenosis >50% but FFR <0.8.
- •7. Contraindication for CCTA (e.g., allergic reactions to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA Visit as assessed by the Imaging Core Lab.
- •8. Pacemaker or implantable cardioverter-defibrillator (ICD) in situ.
- •9. Systolic Left Ventricle Ejection Fraction <30% at the Screening Visit.
- •10. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization (assessed at the Screening Visit) despite antihypertensive therapy.
- •11. Heart failure New York Heart Association (NYHA) class III or class IV at the Screening Visit.
- •12. Renal insufficiency (eGFR <30 mL/min/1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the Screening Visit and at the Statin Optimization 3 Visit.
- •13. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Screening Visit. Participants who enter the Statin Optimization Period must have AST and ALT =3x ULN (as defined by local laboratory reference ranges collected at the Screening Visit) and reported by the Statin Optimization Telephone Visit 1 to be allowed to continue in the Statin Optimization Period.
- •Please refer to Section 5.2 of the study protocol for the complete list of exclusion criteria
Investigators
Similar Trials
Completed
Phase 2
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU377 to placebo after 8 week treatment in patients with essential hypertensiohypertension = high blood pressureincreased arterial pressure10057166NL-OMON31167ovartis50
Active, not recruiting
Phase 1
A Study to Evaluate Mepolizumab Withdrawal After Long-Term Usesevere eosinophilic asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002361-32-NLGlaxoSmithKline Research & Development Ltd306
Active, not recruiting
Phase 1
Study of efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with H1- antihistaminesChronic Inducible UrticariaMedDRA version: 20.0Level: PTClassification code 10009869Term: Cold urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10008675Term: Cholinergic urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 23.0Level: LLTClassification code 10012521Term: DermographismSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-003018-11-GRovartis Pharma AG428
Active, not recruiting
Phase 1
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU377 to placebo after 8 week treatment in patients with essential hypertensioEssential HypertensionEUCTR2007-001360-76-SKOVARTIS PHARMA Services AG1,560
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertensioMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2008-003139-19-NLovartis Pharma Services AG480